Treating lung carcinoid tumors requires a careful approach that depends on the type of tumor, how far it has spread, and the patient’s overall health. While surgery offers the best chance for long-term control in many cases, there are also treatments for advanced disease and ongoing research into new therapies that may help patients in the future.

Approaches to Managing Lung Carcinoid Tumors

Lung carcinoid tumors are a rare form of cancer that starts in the specialized neuroendocrine cells found throughout the lungs. These cells normally help regulate breathing, blood flow, and other lung functions by releasing hormones and responding to signals from the nervous system. When these cells grow out of control, they form tumors that can be classified as either typical or atypical carcinoids, with typical tumors growing more slowly and spreading less often than atypical ones.^[1]

The main goal of treatment is to remove the tumor completely whenever possible, which gives patients the best chance of living without disease for many years. For typical carcinoid tumors, which make up about 85% to 90% of lung carcinoid cases, surgery can be very successful. About 85% to 90% of people with typical carcinoids live at least five years after diagnosis, and many live much longer. For atypical carcinoids, which grow faster and are more likely to spread, the five-year survival rate is between 50% and 70%, though many patients still benefit greatly from treatment.^[7]

Treatment planning depends heavily on several factors. Doctors must consider whether the tumor is typical or atypical, where it is located in the lung (central airways versus outer edges), whether it has spread to lymph nodes or distant organs, and the patient’s overall health and ability to tolerate surgery. Because these tumors are rare, making up only 1% to 2% of all lung cancers, it is recommended that treatment decisions be made through a team approach involving surgeons, lung specialists, cancer doctors, radiologists, and pathologists.^[3][10]

Standard Surgical Treatment

Surgery is the cornerstone of treatment for lung carcinoid tumors and is considered the only approach that can lead to a cure. All patients with carcinoid tumors that have not spread to distant organs should be considered for complete surgical removal, as long as they are healthy enough to undergo the procedure. The primary goal is total removal of the tumor along with examination of nearby lymph nodes to determine if the cancer has spread locally.^[5][9]

The most commonly performed operations include lobectomy (removing one lobe of the lung), segmentectomy (removing a segment of the lung), and in some cases pneumonectomy (removing an entire lung). For patients with limited lung function who might not tolerate losing significant lung tissue, surgeons may perform specialized procedures called bronchoplastic resections or sleeve resections. These techniques allow removal of the tumor while preserving more lung tissue, which can be especially important for patients with breathing problems or other lung conditions.^[9]

During surgery, the surgeon also removes and examines lymph nodes from the chest to check for cancer spread. This lymph node dissection is an essential part of the operation because it helps determine the stage of the disease and whether additional treatment might be needed. Even when lymph nodes contain cancer cells, surgery may still be performed, as complete removal can provide good long-term outcomes for many patients.^[3]

For tumors located in the smaller airways near the edges of the lungs (peripheral carcinoids), a wedge resection may be considered, especially for patients who cannot tolerate more extensive surgery. However, this approach removes less tissue and may not be as thorough, so it is typically reserved for patients with limited lung reserve who would face serious risks from a larger operation.^[9]

Another technique sometimes used is laser photoresection, in which a specialized laser is passed through a bronchoscope to burn away tumor tissue blocking the airways. Like bronchoscopic resection, this is typically used to relieve symptoms or prepare for surgery rather than as a primary treatment. One drawback is that the laser destroys part of the tumor, making it harder for pathologists to examine the tissue and determine whether it is typical or atypical, which is important for planning further care.^[9]

Recovery from lung surgery varies depending on the extent of the operation and the patient’s overall health. Most patients spend several days in the hospital and then need weeks to months to fully recover. During this time, breathing exercises, physical therapy, and gradual return to normal activities are important. Many patients experience shortness of breath initially, especially after larger operations, but this often improves over time as the remaining lung tissue expands and compensates.^[20]

Complications from surgery can include infection, bleeding, prolonged air leak from the lung, pneumonia, and in rare cases, more serious problems such as blood clots or heart rhythm disturbances. The surgical team monitors patients closely to detect and treat any complications early. Overall, modern surgical techniques and perioperative care have made these operations safer, with most patients recovering well.^[20]

Additional Treatments Beyond Surgery

For patients with advanced disease that cannot be completely removed by surgery, or for those whose tumors return after surgery, several other treatment options are available. While no medical therapy can cure lung carcinoid tumors by itself, these approaches can help control the disease, relieve symptoms, and improve quality of life.^[5]

Chemotherapy, which uses drugs to kill cancer cells throughout the body, has been used in patients with metastatic lung carcinoid tumors. However, chemotherapy has generally shown limited effectiveness for these tumors compared to other types of lung cancer. It is most often considered for atypical carcinoids that have spread to distant organs, particularly when symptoms need to be controlled. Common chemotherapy regimens used include combinations of drugs like etoposide with cisplatin or carboplatin, though response rates are modest.^[9][10]

Radiation therapy, which uses high-energy beams to kill cancer cells, also has a limited role in treating lung carcinoid tumors. Like chemotherapy, radiation has not been very effective as a primary treatment for these cancers. It may be used in specific situations, such as relieving symptoms from tumors pressing on airways or nerves, treating areas where cancer has spread to bones or the brain, or in patients who cannot undergo surgery.^[9]

One treatment approach that has shown more promise is the use of somatostatin analogues, which are synthetic versions of a hormone that can slow tumor growth and reduce hormone secretion from neuroendocrine tumors. These drugs, which include medications like octreotide and lanreotide, are particularly helpful for patients with carcinoid syndrome – a condition that occurs when tumors release large amounts of hormones into the bloodstream, causing symptoms like severe diarrhea, facial flushing, and wheezing. Somatostatin analogues can control these symptoms effectively in many patients.^[3][12]

Peptide receptor radionuclide therapy (PRRT) is a newer treatment that combines a radioactive substance with a molecule that binds to receptors on neuroendocrine tumor cells. When injected into the bloodstream, this combination seeks out tumor cells throughout the body and delivers targeted radiation directly to them. PRRT has shown promise in treating advanced neuroendocrine tumors and may be considered for patients with metastatic lung carcinoids, though more research is needed to determine the best use of this therapy in lung carcinoid tumors specifically.^[3][10]

For some patients whose cancer has spread but only to isolated areas that can be reached with surgery, resection of these metastatic lesions may be considered. For example, if a lung carcinoid has spread to just one or two spots in the liver, removing those spots surgically might help some patients live longer. This approach requires careful evaluation to ensure that the cancer is truly limited to a few removable sites.^[9]

Treatment in Clinical Trials and Emerging Therapies

Because lung carcinoid tumors are rare and standard treatments beyond surgery have limited effectiveness, there is great interest in developing new therapies through clinical trials. These research studies test promising new drugs and approaches to see if they can help patients better than existing treatments. Several areas of investigation are currently underway.^[10]

Targeted therapy represents one important area of research. Scientists have been studying the molecular changes that occur in carcinoid tumor cells to identify specific pathways that drive tumor growth. Some clinical trials are testing drugs that target these pathways. For example, drugs called mTOR inhibitors work by blocking a protein pathway that helps tumors grow and make new blood vessels. Another class being studied includes drugs targeting vascular endothelial growth factor (VEGF), which tumors use to build the blood supply they need to grow. While results have been mixed so far, research continues to identify which patients might benefit most from these approaches.^[10]

Immunotherapy has revolutionized the treatment of many cancers by helping the body’s own immune system recognize and attack tumor cells. Clinical trials are exploring whether immunotherapy drugs might help patients with lung carcinoid tumors. These drugs, called immune checkpoint inhibitors, remove the brakes that tumors use to hide from the immune system. Drugs like pembrolizumab, nivolumab, and others are being tested in neuroendocrine tumors to see if they can produce meaningful responses. Early results suggest that some patients may benefit, though more research is needed to understand which patients are most likely to respond.^[3][10]

Researchers are also investigating combinations of different treatments. For example, some trials are testing whether combining immunotherapy with targeted drugs or with peptide receptor radionuclide therapy might work better than any single treatment alone. The rationale is that attacking tumors in multiple ways simultaneously might overcome resistance that develops when using just one approach.

Clinical trials typically proceed through three phases. Phase I trials focus mainly on safety – determining what dose of a new drug can be given without causing unacceptable side effects. Phase II trials look at whether the drug shows evidence of working against the cancer, measuring responses like tumor shrinkage or slower growth. Phase III trials compare the new treatment to the current standard treatment to see if the new approach is better. Patients may be eligible for trials at any of these phases depending on their specific situation.^[10]

To participate in a clinical trial, patients must meet specific eligibility criteria, which typically include factors like the type and stage of their cancer, previous treatments received, and overall health status. Trials are conducted at specialized medical centers in many countries, including the United States, Europe, and other regions. Patients interested in clinical trials should discuss this option with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks.^[3]

Addressing Symptoms and Hormone-Related Problems

Some patients with lung carcinoid tumors experience symptoms related to the hormones that these tumors can produce. The most recognized condition is carcinoid syndrome, which occurs when tumors release large amounts of serotonin and other substances into the bloodstream. This is more common in patients with large tumors or when the cancer has spread to the liver, though it occurs less frequently with lung carcinoids than with carcinoid tumors arising in the digestive tract.^[1][5]

Symptoms of carcinoid syndrome include severe watery diarrhea, episodes of facial flushing (sudden redness and warmth of the face and neck), wheezing, rapid heartbeat, and sometimes dangerous drops in blood pressure. These symptoms can significantly affect quality of life and require specific treatment. Somatostatin analogues are the main treatment for carcinoid syndrome, as they can reduce hormone release from tumor cells and control symptoms in most patients. The medications are typically given as injections, either under the skin daily or as longer-acting monthly injections.^[1][4]

Some lung carcinoid tumors can also produce other hormones that cause different problems. For example, a small percentage of tumors produce adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to make too much cortisol. This causes ectopic Cushing’s syndrome, leading to symptoms like rapid weight gain (especially in the face and upper back), high blood sugar, high blood pressure, muscle weakness, and easy bruising. Treatment focuses on removing the tumor if possible or using medications that block cortisol production.^[3][5]

Most Common Treatment Methods

• Surgical Resection
  • Lobectomy – removal of one lobe of the lung, the most common operation for lung carcinoid tumors
  • Segmentectomy – removal of a lung segment, preserving more lung tissue
  • Pneumonectomy – removal of an entire lung, reserved for large or centrally located tumors
  • Sleeve resection and bronchoplastic procedures – specialized techniques that remove tumor while preserving lung function
  • Wedge resection – removal of a small tumor and surrounding tissue, typically for peripheral tumors in patients with limited lung reserve
  • Lymph node dissection performed during all surgical procedures to determine cancer spread
• Hormone-Controlling Medications
  • Somatostatin analogues (octreotide, lanreotide) – reduce hormone production and control carcinoid syndrome symptoms
  • Can help control diarrhea, flushing, and other hormone-related symptoms
  • May also have some effect in slowing tumor growth
• Targeted Radiation Therapy
  • Peptide receptor radionuclide therapy (PRRT) – delivers targeted radiation to tumor cells throughout the body
  • Combines radioactive substance with molecules that bind to receptors on neuroendocrine tumor cells
  • Used for patients with advanced disease that has spread to multiple sites
• Chemotherapy
  • Combinations of drugs like etoposide with platinum-based agents (cisplatin or carboplatin)
  • Generally has limited effectiveness for typical carcinoids
  • May be considered for atypical carcinoids with metastatic disease
  • Used mainly when other treatments are not sufficient to control disease
• Palliative Procedures
  • Bronchoscopic resection – removing tumor tissue through an airway tube to relieve obstruction
  • Laser photoresection – using laser energy to remove tumor blocking airways
  • External beam radiation – targeting specific areas causing symptoms or controlling brain or bone metastases
  • These approaches focus on symptom relief rather than cure
• Experimental Approaches in Clinical Trials
  • mTOR inhibitors and other targeted drugs blocking specific tumor growth pathways
  • Immunotherapy with checkpoint inhibitors to enhance immune system recognition of tumor cells
  • VEGF inhibitors targeting tumor blood vessel formation
  • Combination therapies testing multiple approaches together

Following Treatment and Long-Term Care

After completing treatment, patients with lung carcinoid tumors require ongoing monitoring to detect any return of cancer and to manage any lasting effects of treatment. Because these tumors can recur even many years after surgery, long-term follow-up is essential. Most doctors recommend regular visits that include physical examination, imaging tests like CT scans, and in some cases blood tests to measure tumor markers.^[15]

The frequency of follow-up visits typically depends on the type of carcinoid (typical versus atypical), the stage at diagnosis, and whether the tumor was completely removed. Generally, more frequent monitoring is recommended in the first few years after treatment, when recurrence is most likely. For typical carcinoids that were completely removed, some patients may eventually transition to less frequent monitoring if no problems are detected. For atypical carcinoids, more intensive and prolonged surveillance is usually recommended because of the higher risk of recurrence.^[15]

Patients should report any new symptoms to their doctor promptly, including persistent cough, coughing up blood, chest pain, shortness of breath, unexplained weight loss, or symptoms suggesting carcinoid syndrome. While these symptoms can have many causes, they may indicate tumor recurrence or progression and should be evaluated.

Quality of life after lung surgery can vary. Many patients who undergo limited resections like lobectomy recover well and return to normal activities. Those who have had larger operations may experience more lasting effects on their breathing capacity, particularly during vigorous exercise. Pulmonary rehabilitation programs, which include breathing exercises, physical conditioning, and education, can help patients maximize their recovery and adjust to any changes in lung function.^[20]

Emotional and psychological support is also important. Living with a cancer diagnosis, even one with a generally favorable outlook, can cause anxiety, fear of recurrence, and other emotional challenges. Many patients benefit from talking with counselors, joining support groups with other neuroendocrine tumor patients, or connecting with patient advocacy organizations that provide information and peer support.^[18][19]